絞り込み

16546

広告

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.

著者 Martin N , Isambert N , Gomez-Roca C , Goeldner RG , Zanetta S , Sadrolhefazi B , de Mont-Serrat H , Campone M , Delord JP
Cancer Chemother Pharmacol.2018 Oct 22 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (19view , 0users)

Full Text Sources

Miscellaneous

Trastuzumab is the mainstay of therapy for patients with HER2-positive breast and gastric cancer but resistance frequently occurs. Afatinib, an irreversible oral ErbB family blocker, shows clinical activity in trastuzumab-refractory HER2-positive metastatic breast cancer.
PMID: 30350178 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード